Join
Live feed
·
NEWSReleasevia Quantisnow
Rani Therapeutics Holdings Inc. logo

Rani Therapeutics Has Entered Into A Definitive Agreement With ProGen For The Co-development And Commercialization Of RT-114, An Oral Ranipill Capsule Containing ProGen's PG-102, A GLP-1/GLP-2 Dual Agonist, For Obesity

ByQuantisnow·Wall Street's wire, on your screen.
RANI· Rani Therapeutics Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RANI (Rani Therapeutics Holdings Inc.) and more on Quantisnow.